Ichnos Glenmark to Present Updated Phase 1 Data on ISB 2001 in Multiple Myeloma at ASH 2026

manufacturing-news
Lida Pacaud, President and Chief Executive Officer of Ichnos Glenmark Innovation

Ichnos Glenmark Innovation, Inc (IGI), a clinical-stage biotechnology company focused on developing multispecific therapeutics in oncology, will present updated clinical data from the Phase 1 study of ISB 2001 (ABBV-2001) in patients with relapsed or refractory multiple myeloma (RRMM) at the 68th Annual Meeting of the American Society of Hematology (ASH). The data will be shared in an oral presentation on December 12, 2026, in New Orleans, Louisiana.

The presentation will include longer-term follow-up from the dose-escalation phase and initial findings from dose expansion in the Phase 1 TRIgnite-1 study. According to IGI, the updated results demonstrate promising efficacy and tolerability in heavily pretreated patients with RRMM.

ISB 2001 (ABBV-2001) is an investigational trispecific T-cell engager designed to target CD38 and BCMA on multiple myeloma cells, while engaging CD3 on T cells. Developed using IGI’s proprietary BEAT® Multispecific Platform, the molecule is designed to coordinate recognition of two tumour antigens with T-cell engagement through a single molecular structure.

Lida Pacaud, MD., President and Chief Executive Officer of IGI, said, “With longer follow-up from dose escalation and initial results from dose expansion, ISB 2001 (ABBV-2001) continues to demonstrate robust efficacy and tolerability in heavily pretreated patients with relapsed/refractory multiple myeloma. These results represent an important milestone in the development of this first and only trispecific T-cell engager targeting CD38 x BCMA x CD3. Together with our partner, AbbVie, we remain focused on advancing ISB 2001 (ABBV-2001) as a potential new treatment option for patients with relapsed/refractory multiple myeloma (RRMM).”

The oral presentation is titled “First- and only-in-class CD38 x BCMA x CD3 trispecific T-cell engager ISB 2001 (ABBV-2001): Updated Phase 1 (TRIgnite-1) study data demonstrate robust efficacy and tolerability in relapsed/refractory multiple myeloma (RRMM).” It will be delivered by Dr. Binod Dhakal of the Medical College of Wisconsin on Saturday, December 12, 2026, from 4:00 pm to 4:15 pm CST. The presentation will take place in La Nouvelle C at the Ernest N. Morial Convention Center, during Session 654, “Multiple Myeloma: Pharmacologic Therapies: The March of Immunotherapy”.

IGI and AbbVie entered into an exclusive global licensing agreement for ISB 2001 in July 2025. The candidate is being evaluated in multiple myeloma through the Phase 1 TRIgnite-1 study and a Phase 1/2 combination study. It remains investigational and has not been approved for commercial use.

Ichnos Glenmark Innovation is a fully integrated, clinical-stage biotechnology company headquartered in New York, focused on developing innovative biologics for oncology. Its pipeline includes novel multispecific therapeutics designed to address complex diseases, with a focus on haematological malignancies and solid tumours. The company’s research and development programmes are powered by its proprietary BEAT® technology platform, which supports the development of multispecific molecules intended to improve treatment options for patients.